Memorial Sloan-Kettering Cancer Center (MSKCC) is the largerst privately owneed nonprofit cancer center in the world. The Center consists of 3 corporations. Memorial Hospital for Cancer and Allied Diseases, foundin in 1884 is the clinical unit;Sloan-Kettering Institute for Cancer Research, founded in 1945 is the basic research unit;and Memorial Sloan-Kettering Cancer Center, founded in 1960 is the unit that formulates policies and long-range plans and coordinates the activities of the hospital and the institute. MSKCC is a free-standing institution committed to exceptional in-patient and out-patient care, leading edge research and superb clinical and research training programs. MSKCC's clinical research programs are synonymous with those of the Cancer and Leukemia Group B (CALGB). Physician-scientists at MSKCC hold leadership positions in the CALGB across an array of disease-specific areas and treatment modalities, with significant administrative responsibilities for the group. Scientific and clinical research programs at MSKCC are created with the intention of ultimately testing them, when possible, in the larger patient populations offered by our participation in the CALGB. During the next six years, MSKCC will continue to expand its clinical and research facilities as well as its research and training programs. The enclosed grant offers examples of MSKCC contributions to the success of the CALGB and support for MSKCC's continued participation.

Public Health Relevance

MSKCC's research programs are specifically designed to utilize the large patient population and broad, multi-disciplinary staff of clinical and laboratory based investigators while stimulating the application of discoveries in the basic sciences to promote the prevention, detection, diagnosis and treatment of many forms of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA077651-16
Application #
8450282
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1998-07-30
Project End
2014-02-28
Budget Start
2013-04-01
Budget End
2014-02-28
Support Year
16
Fiscal Year
2013
Total Cost
$194,694
Indirect Cost
$92,223
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Straus, David J; Jung, Sin-Ho; Pitcher, Brandelyn et al. (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013-1021
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Mandelblatt, Jeanne S; Cai, Ling; Luta, George et al. (2017) Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Res Treat 164:107-117
Freedman, Rachel A; Foster, Jared C; Seisler, Drew K et al. (2017) Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. J Clin Oncol 35:421-431
Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442
Partridge, Ann H; Sepucha, Karen; O'Neill, Anne et al. (2017) Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy? Breast Cancer Res Treat 165:545-553
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Fuchs, Charles S; Niedzwiecki, Donna; Mamon, Harvey J et al. (2017) Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol 35:3671-3677

Showing the most recent 10 out of 104 publications